Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor

Cancer Gene Therapy volume 12, pages 268–275 (2005)Cite this article

Abstract

Human ribonuclease inhibitor (hRI) is an acid protein with a molecular weight of 50 kDa. It can inhibit the activity of pancreatic RNase (RNase A). Angiogenin (Ang) is a member of the ribonuclease super family. It has 35% identity with RNase A and contains ribonucleolytic activity. The substrate specificity of angiogenin seems, however, to be more restricted than that of the pancreatic RNase. Since Ang is an important angiogenic factor and RI is a highly efficient inhibitor of Ang, it can be hypothesized that RI may be a latent antiangiogenic drug. This study focuses on the feasibility of transfecting the ri gene into mice hematopoietic cells and inducing the expression of the ri gene to block the angiogenesis of solid tumors. First, the cDNA gene of the ri from human placenta was cloned and inserted in a retroviral vector, pLNCX. The combined vector pLNCX-ri was transfected into retroviral packaging cells, PA317, and a clone producing a high titer of virus was obtained. Next, isolated hematopoietic cells from mice bone marrow were infected with viruses carrying the pLNCX-ri. The infected cells were then injected into lethally irradiated mice. The expression and the contribution of RI were assayed in vivo. After administration of hematopoietic cells carrying the ri gene, mice were implanted with B16 melanomas for 21 days. The results showed that tumors of control groups became large and well vascularized. In contrast, tumors from mice groups treated with hematopoietic cells carrying the ri gene were small and possessed a relatively low density of blood vessels. The inhibited growth rate of the tumors was 47%. This study demonstrated the potential utility of gene therapy for systemic delivery of a novel antiangiogenic agent — hRI.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Fidler IJ . Modulation of the organ microenvironment for treatment of cancer matastasis. J Natl Cancer Inst. 1995;87:1588–1592.

    Article  CAS  Google Scholar 

  2. Bouck N, Stellmach V, Hsu S . How tumors become angiogenic. Cancer Res. 1996;69:135–174.

    Article  CAS  Google Scholar 

  3. Joe Y-A, Hong Y-K, Chung D-S, Yang J-K, Lee Y-S . Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles1-3. Int J Cancer. 1999;82:694–699.

    Article  CAS  Google Scholar 

  4. Drixler TA, Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE . Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 2000;60:1761–1765.

    CAS  Google Scholar 

  5. Folkman J . The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat. 1995;36:109–118.

    Article  CAS  Google Scholar 

  6. Fett JW, Strydom DJ, Vallee BL . Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985;24:5480–5486.

    Article  CAS  Google Scholar 

  7. Bikfalvi A, Klein S, Pintucci G, et al. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor possible intracellular signaling by the high molecular weight forms. J Cell Biol. 1995;129:233–243.

    Article  CAS  Google Scholar 

  8. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis,and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA. 1998;95:10820–10825.

    Article  CAS  Google Scholar 

  9. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159–165.

    Article  CAS  Google Scholar 

  10. Kurachi K, Davie EW, Vallee BL . Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry. 1985;24:5494–5499.

    Article  CAS  Google Scholar 

  11. Drixler TA, Rinkes IH, Ritchie ED, et al. Continuous administration of angistatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 2000;60:1761–1765.

    CAS  Google Scholar 

  12. Folkman J . Antiangiogenetic gene therapy. Proc Natl Acad Sci USA. 1998;95:9064–9066.

    Article  CAS  Google Scholar 

  13. Rybak SM, Sanovich E, Hollingshead MG, et al. “Vasocrine” formation of tumor cell- lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res. 2003;63:2812–2819.

    CAS  PubMed  Google Scholar 

  14. Drevs J, Laus C, Mendinger M, Schmidt-Gersbach C, Unger C . Antiangiogenesis: Current clinical data and future perspectives. Onkologie. 2002;25:520–527.

    CAS  PubMed  Google Scholar 

  15. Xiuping Y, Yuxiang T, Xiuyun C . Cloning and sequencing of ribonuclease inhibitor. J Pract Oncol. 2000;15:230–232.

    Google Scholar 

  16. Frederick MA . Short Protocols in Molecular Biology. 3rd edn. Science Publication Press: Beijing, China; 1998: 319–320 (in Chinese).

    Google Scholar 

  17. Roth JA, Cristiano RJ . Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21–39.

    Article  CAS  Google Scholar 

  18. Dunbar CE . Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med. 1996;47:11–20.

    Article  CAS  Google Scholar 

  19. Brenner MK . Gene transfer to hematopoietic cells. N Engl J Med. 1996;335:337–339.

    Article  CAS  Google Scholar 

  20. Kerr WG, Mule JJ . Gene therapy: current status and future propects. J Leukoc Biol. 1994;56:210–214.

    Article  CAS  Google Scholar 

  21. Hanford HA, Wong CA, Kassan H, et al. Angiostatin4.5-mediated apoptosis of vascular endothelial cells. Cancer Res. 2003;63:4275–4280.

    CAS  PubMed  Google Scholar 

  22. O'Reilly MS, Boehm T, Shing Y . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1999;88:277–285.

    Article  Google Scholar 

  23. Polakowski IJ, Lewis MK, Muthukkaruppan VR, et al. A ribonuclease inhibitor expresses antiangiogenic properties and leads to reduced tumor growth in mice. Am J Pathol. 1993;143:507–517.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Rafael B-E, Gema M, Fernando R, et al. Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor RNasin. Cancer Gene Ther. 2001;8:278–284.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, 116027, China

    Panfeng Fu, Junxia Chen, Yuxiang Tian, Xiuyun Cui & Baochang Zhao

  2. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21224, USA

    Tonya Watkins

Authors
  1. Panfeng Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junxia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuxiang Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tonya Watkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiuyun Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Baochang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiuyun Cui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fu, P., Chen, J., Tian, Y. et al. Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor. Cancer Gene Ther 12, 268–275 (2005). https://doi.org/10.1038/sj.cgt.7700742

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700742

Keywords

This article is cited by

Search

Advanced search

Quick links